AUTOLUS THERAPEUTICS PLC (AUTL) Stock Price, Quote, News and Overview
NASDAQ:AUTL - Nasdaq - US05280R1005 - ADR - Currency: USD
AUTL Quote, Performance and Key Statistics
NASDAQ:AUTL (5/12/2025, 2:14:45 PM)
1.39
+0.07 (+5.3%)
The current stock price of AUTL is 1.39 USD. In the past month the price increased by 15.79%. In the past year, price decreased by -66.92%.
AUTL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.64 | 338.71B | ||
| AMGN | AMGEN INC | 13.23 | 147.69B | ||
| GILD | GILEAD SCIENCES INC | 13.41 | 129.26B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.93 | 61.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.73B | ||
| ARGX | ARGENX SE - ADR | 95.21 | 34.13B | ||
| ONC | BEIGENE LTD-ADR | 5.78 | 24.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.25B | ||
| NTRA | NATERA INC | N/A | 21.09B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.30B | ||
| BIIB | BIOGEN INC | 7.85 | 18.19B |
Related stock screener links
About AUTL
Company Profile
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The company is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. The company has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Company Info
AUTOLUS THERAPEUTICS PLC
The Mediaworks, 191 Wood Lane
London W12 7RZ GB
CEO: Christian Itin
Employees: 649
Phone: 442038296230
AUTOLUS THERAPEUTICS PLC / AUTL FAQ
What is the stock price of AUTOLUS THERAPEUTICS PLC today?
The current stock price of AUTL is 1.39 USD. The price increased by 5.3% in the last trading session.
What is the ticker symbol for AUTOLUS THERAPEUTICS PLC stock?
The exchange symbol of AUTOLUS THERAPEUTICS PLC is AUTL and it is listed on the Nasdaq exchange.
On which exchange is AUTL stock listed?
AUTL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AUTOLUS THERAPEUTICS PLC stock?
17 analysts have analysed AUTL and the average price target is 10.01 USD. This implies a price increase of 619.87% is expected in the next year compared to the current price of 1.39. Check the AUTOLUS THERAPEUTICS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AUTOLUS THERAPEUTICS PLC worth?
AUTOLUS THERAPEUTICS PLC (AUTL) has a market capitalization of 369.92M USD. This makes AUTL a Small Cap stock.
How many employees does AUTOLUS THERAPEUTICS PLC have?
AUTOLUS THERAPEUTICS PLC (AUTL) currently has 649 employees.
What are the support and resistance levels for AUTOLUS THERAPEUTICS PLC (AUTL) stock?
AUTOLUS THERAPEUTICS PLC (AUTL) has a resistance level at 1.36. Check the full technical report for a detailed analysis of AUTL support and resistance levels.
Is AUTOLUS THERAPEUTICS PLC (AUTL) expected to grow?
The Revenue of AUTOLUS THERAPEUTICS PLC (AUTL) is expected to grow by 191.2% in the next year. Check the estimates tab for more information on the AUTL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AUTOLUS THERAPEUTICS PLC (AUTL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AUTL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AUTL, evaluating the profitability, health, valuation and growth aspects
- AUTOLUS THERAPEUTICS PLC (AUTL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AUTOLUS THERAPEUTICS PLC (AUTL) Sales and EPS estimates to see what analysts future expectations are.
- AUTOLUS THERAPEUTICS PLC (AUTL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AUTOLUS THERAPEUTICS PLC (AUTL) Insider and Institutional Ownership to learn about the owners and their transactions.
- AUTOLUS THERAPEUTICS PLC (AUTL) Stock Chart to make your own analysis
- AUTOLUS THERAPEUTICS PLC (AUTL) Latest news and press-releases to stay up to date.
Does AUTOLUS THERAPEUTICS PLC (AUTL) stock pay dividends?
AUTL does not pay a dividend.
What is the Price/Earnings (PE) ratio of AUTOLUS THERAPEUTICS PLC (AUTL)?
AUTOLUS THERAPEUTICS PLC (AUTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.89).
What is the Short Interest ratio of AUTOLUS THERAPEUTICS PLC (AUTL) stock?
The outstanding short interest for AUTOLUS THERAPEUTICS PLC (AUTL) is 5.36% of its float. Check the ownership tab for more information on the AUTL short interest.
AUTL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AUTL. When comparing the yearly performance of all stocks, AUTL is a bad performer in the overall market: 93.99% of all stocks are doing better.
AUTL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AUTL. AUTL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AUTL Financial Highlights
Over the last trailing twelve months AUTL reported a non-GAAP Earnings per Share(EPS) of -0.89. The EPS increased by 26.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.19% | ||
| ROE | -51.64% | ||
| Debt/Equity | 0.57 |
AUTL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to AUTL. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -6.05% and a revenue growth 191.2% for AUTL